NASDAQ:NTRB - Nasdaq - US67092M2089 - Common Stock - Currency: USD
7.46
+0.08 (+1.08%)
The current stock price of NTRB is 7.46 USD. In the past month the price decreased by -24.65%. In the past year, price increased by 210.83%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
NUTRIBAND INC
121 S Orange Ave Ste 1500
Orlando FLORIDA US
CEO: Gareth Sheridan
Employees: 13
Company Website: https://nutriband.com/
Investor Relations: http://www.nutriband.com/investors
Phone: 14073776695
The current stock price of NTRB is 7.46 USD. The price increased by 1.08% in the last trading session.
The exchange symbol of NUTRIBAND INC is NTRB and it is listed on the Nasdaq exchange.
NTRB stock is listed on the Nasdaq exchange.
7 analysts have analysed NTRB and the average price target is 13.26 USD. This implies a price increase of 77.75% is expected in the next year compared to the current price of 7.46. Check the NUTRIBAND INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NUTRIBAND INC (NTRB) has a market capitalization of 82.88M USD. This makes NTRB a Micro Cap stock.
NUTRIBAND INC (NTRB) currently has 13 employees.
NUTRIBAND INC (NTRB) has a support level at 7.25. Check the full technical report for a detailed analysis of NTRB support and resistance levels.
The Revenue of NUTRIBAND INC (NTRB) is expected to decline by -32.1% in the next year. Check the estimates tab for more information on the NTRB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NTRB does not pay a dividend.
NUTRIBAND INC (NTRB) will report earnings on 2025-04-28, after the market close.
NUTRIBAND INC (NTRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.71).
The outstanding short interest for NUTRIBAND INC (NTRB) is 7.94% of its float. Check the ownership tab for more information on the NTRB short interest.
ChartMill assigns a technical rating of 10 / 10 to NTRB. When comparing the yearly performance of all stocks, NTRB is one of the better performing stocks in the market, outperforming 98.28% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to NTRB. While NTRB seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months NTRB reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS decreased by -6.01% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -54.59% | ||
ROE | -60.96% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 83% to NTRB. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -160.87% and a revenue growth -32.1% for NTRB